Tarsus Pharmaceuticals (TARS) Cash & Equivalents (2019 - 2026)

Tarsus Pharmaceuticals' Cash & Equivalents history runs 8 years deep, the most recent figure standing at $102.2 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 41.87% year-over-year to $102.2 million; the TTM figure through Mar 2026 stood at $102.2 million (down 41.87% YoY), while the FY2025 annual figure was $183.6 million, up 93.68% from the prior year.
• Cash & Equivalents was $102.2 million for Q1 2026 at Tarsus Pharmaceuticals, down from $183.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $245.4 million in Q2 2022 to a low of $66.0 million in Q1 2023.
• Historically, Cash & Equivalents has averaged $153.1 million across 5 years, with a median of $175.0 million in 2022.
• Biggest YoY gain for Cash & Equivalents was 213.91% in 2023; the steepest drop was 62.29% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $71.7 million in 2022, then jumped by 213.91% to $224.9 million in 2023, then sank by 57.85% to $94.8 million in 2024, then surged by 93.68% to $183.6 million in 2025, then slumped by 44.35% to $102.2 million in 2026.
• The last three Cash & Equivalents figures came in at $102.2 million (Q1 2026), $183.6 million (Q4 2025), and $112.7 million (Q3 2025), per Business Quant data.